Haixi New Drugs (02637): HX9428 has been granted Fast Track designation by the U.S. FDA for the treatment of neovascular age-related macular degeneration.

Zhihui Finance APP reported that Haixi New Drug (02637) announced that its self-developed innovative drug project HXP056 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the candidate drug molecule HX9428, aimed at treating neovascular age-related macular degeneration (nAMD), also known as wet age-related macular degeneration (wAMD). The granting of FTD qualification will facilitate closer communication between the company and the FDA regarding the clinical development of HX9428, advancing its global clinical development progress.